Recent String of Deadly Tornadoes Reminds us that Mass Casualty Events can Happen with Little or No Warning
FDA Grants Emergency Use Authorization for Two Oral Antiviral Drugs to Treat COVID-19: Pfizer’s Paxlovid and Merck’s Molnupiravir
HHS-ASPR to Oversee Fair and Equitable Allocation
This week, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization to Pfizer for paxlovid and Merck for molnupiravir, both oral antiviral drugs now authorized for the treatment of mild to moderate COVID-19 in adult patients age 18 years and older who are at high risk for progressing to severe COVID-19. Paxlovid is also authorized for use in pediatric patients age 12 years and older.
The federal government has purchased 10 million courses of paxlovid and 3 million courses of molnupiravir. The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) will oversee the fair and equitable allocation of each drug to state and territorial health departments.
FDA Issues EUA for Evusheld for the
Prevention of COVID-19 in Certain
Adults and Pediatric Individuals;
HHS-ASPR to Lead Federal Allocation
and Distribution of Product
PROVIDENCE, R.I. – Attorney General Peter F. Neronha announced that a Providence man has been sentenced in Providence County Superior Court to serve...
